Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kevin Buchi Insider Profile
4 Followers
Kevin Buchi, President & CEO, Director at Tetralogic Pharma, holds 23.87K shares in Amneal Pharmaceuticals (Ticker: AMRX), holds 330.71K shares in Tetralogic Pharma (Ticker: TLOG), holds ― shares in Dicerna Pharma (Ticker: DRNA).
Kevin Buchi Tetralogic Pharma (TLOG)President & CEO, Director
Tetralogic Pharma (TLOG)
President & CEO, Director
Ranked #75,786 out of 78,624 Corporate Insiders
Profitable Transactions
1 out of 8 Profitable Transactions
Average Return
-45.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Kevin Buchi holds in companies
Most Profitable Insider Trade
Stock:
Stemline Therapeutics
(STML)
(STML)
Rating:Informative Buy
Date:Jan 30, 2013 - Jan 30, 2014
Return:+127.70%
The most profitable trade made by Kevin Buchi
Kevin Buchi's Trading History
Tetralogic Pharma
Mar 30, 2015
President & CEO, Director
Informative Buy
21.10K
$3.31K
Amneal Pharmaceuticals
May 07, 2020
Director
Uninformative Buy
―
$97.14K
Dicerna Pharma
―
Director
―
―
Biospecifics Technologies
―
Chief Executive Officer, Director
―
―
Ziopharm Oncology
―
Director
―
―
Stemline Therapeutics
Jun 25, 2015
―
Uninformative Buy
―
$281.22K
Alexza Pharmaceuticals
―
―
―
$0.00
Epirus Biopharma
―
Director
―
$0.00
List of latest transactions for each holding click on a transaction to see Kevin Buchi's performance on stock
You May Also Like
Kevin Buchi insider profile FAQ
What is the percentage of profitable transactions made by Kevin Buchi?
The percentage of profitable transactions made by Kevin Buchi is 13%.
What is the average return per transaction made by Kevin Buchi?
The average return per transaction made by Kevin Buchi is -45.10%.
What stocks does Kevin Buchi hold?
Kevin Buchi holds: TLOG, AMRX, DRNA, BSTC, ZIOP, STML, ALXA, EPRSQ stocks.
What was Kevin Buchi’s latest transaction?
Kevin Buchi latest transaction was an Uninformative Buy of ―.
What was Kevin Buchi's most profitable transaction?
Kevin Buchi’s most profitable transaction was an Informative Buy of STML stock on January 30, 2013. The return on the trade was 127.70%.
What is Kevin Buchi's role in Tetralogic Pharma?
Kevin Buchi's role in Tetralogic Pharma is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.